SEC Form 4 · accession 0001562180-16-003884
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shalini Sharp
Officer — CFO & Executive Vice President
Period of report
Dec 23, 2016
Accepted (ET)
Dec 23, 2016 · 4:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 23, 2016 | M | 6,500 | $0.81 | A | 51,887 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.815 | Dec 23, 2016 | M | 6,500 | D | — | Aug 1, 2022 | Common Stock | 6,500 | 56,163 | D |
Explanation of responses
- F11/4 of the option vested one year from May 21, 2012 and then 1/48th monthly thereafter.
Remarks
Exhibit 24 - POA